adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
biotech · Cholangiocarcinoma · Irritable Bowel Syndrome With Diarrhea · RDHL
RedHill Biopharma
RedHill Biopharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
8045 Arco Corporate Drive, Suite 120, Raleigh, NC 27617, US HQ
2009 Founded
43 Employees
Public company Type
RDHL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 8045 Arco Corporate Drive, Suite 120, Raleigh, NC 27617, US
- Founded
- 2009
- Employees
- 43
- Programs
- 14
- Drugs
- 10
- Patents
- 40
RedHill Biopharma pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
RedHill Biopharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to RedHill Biopharma in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in RedHill Biopharma's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.
- Target
- Bacterial DNA-directed RNA polymerase
- Mechanism
- Bacterial DNA-directed RNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: DNA-directed RNA polymerase.
- Target
- DNA-directed RNA polymerase
- Mechanism
- DNA-directed RNA polymerase inhibitor
-
Development asset linked to RedHill Biopharma in public FDA and regional records.
-
Development asset linked to RedHill Biopharma in public FDA and regional records.